Topic resource collection
Approved comparison material connected to this topic.
94 resourcesRead both sides
Growth Hormone-Releasing Peptides (CJC-1295, Ipamorelin, GHRP-2) Stimulate pituitary GH secretion via ghrelin receptor activation Increased IGF-1 levels, improved recovery, enhanced body composition 100–200 mcg subcutaneously bef…
BPC-157 peptide VEGF upregulation, angiogenesis enhancement, tight junction stabilization Preclinical animal models (high quality), human case reports (limited) Direct epithelial regeneration demonstrated in rodent IBD models 10 …
GH Secretagogues (GHRP-2, Ipamorelin) Ghrelin receptor agonism → pituitary GH release 0.8–1.5kg Moderate. Via enhanced sleep quality $80–$140 Best evidence for measurable hypertrophy when stacked with GHRH analogue GHRH Analogues…
Tendon-bone healing (ACL repair) 8–12 weeks to weight-bearing 5–8 weeks to weight-bearing 30–40% faster return to activity; documented in 2024 AJSM study Surgical site infection rate 2–5% (varies by procedure) 0.8–2.1% with BPC-1…
Peptides occupy a unique space between conservative management (NSAIDs, physical therapy) and invasive procedures (corticosteroid injections, surgery). Understanding where they fit requires comparing mechanisms, timelines, and ou…
BPC-157 Peptide Upregulates VEGF and collagen synthesis; enhances fibroblast migration 4–8 weeks for peak benefit Increases Type I collagen density by 40–60% (animal data) Lower. Strengthens tendon structure Evidence strongest in…
Cerebrolysin NGF/BDNF mimetic. Synaptic remodeling and acetylcholine synthesis 5–30mL IV or IM, 2–3x weekly Refrigerate 2–8°C; avoid freezing Pre-mixed solution. Use within 28 days after opening Strong clinical evidence in MCI an…
Every peptide mentioned so far shows promise in preclinical research. But preclinical means animal models, isolated cell cultures, or small human safety trials. No peptide has completed a Phase 3 randomized controlled trial for A…
CJC-1295/Ipamorelin GHRH analog + ghrelin mimetic. Synergistic GH release without cortisol elevation +1.2–2.6 kg over 12–24 weeks (DEXA-measured) Visceral fat reduction 8–12% in deficit or maintenance intake Subcutaneous injectio…
MK 677 Growth hormone secretagogue; increases IGF-1 and mitochondrial biogenesis VO2 max, lactate threshold, glycogen storage rate 10-25mg daily, oral Best-supported peptide for endurance; effects are training-dependent and requi…
BPC-157 VEGF receptor activation promotes angiogenesis; inhibits NF-kB inflammatory pathway Osteoarthritis, meniscus tears, patellar tendinopathy 250–500mcg daily, IM or SubQ injection, 8–12 weeks Multiple human trials showing 34…
BPC-157 Peptide Upregulates VEGF receptor signaling, promotes angiogenesis and fibroblast migration 4–8 weeks in animal models (40–60% faster than controls) Multiple rat and equine studies; no human RCTs Requires injection; dosin…
BPC-157 VEGF receptor activation, fibroblast recruitment, collagen synthesis Strong preclinical (rat/rabbit models), no human RCTs 10–50 mcg/kg daily Most studied for ligament/tendon repair. Mechanism is well-characterized, human…
BPC-157 Musculoskeletal, Neuropathic Angiogenesis, Growth Factor Signaling, MMP Inhibition 64% pain reduction in tendinopathy (JOSR 2020) 250–500 mcg subcutaneous twice daily Strongest evidence for structural tissue repair drivin…
Before selecting a peptide protocol, understand how the major classes differ in mechanism, evidence strength, and suitability for specific scar subtypes. Copper Peptide (GHK-Cu) TGF- pathway activation, lysyl oxidase stimulation,…
The mechanism by which peptides help with chronic pain differs fundamentally from how analgesics work. NSAIDs (non-steroidal anti-inflammatory drugs) inhibit cyclooxygenase enzymes, blocking prostaglandin synthesis. Effective for…
Growth Hormone Secretagogues (MK 677, Ipamorelin, CJC-1295) Stimulate pituitary GH release → increases IGF-1 → supports testicular Leydig cell function 15–27% increase in clinical trials over 8–16 weeks in men with intact testicu…
Before choosing a peptide protocol, understanding how peptides stack up against conventional eczema therapies clarifies where they fit in a treatment plan. Topical peptides (barrier-repair formulations) Stimulate filaggrin synthe…
Thymosin alpha-1 Enhances Treg function, reduces IL-17A and TNF-alpha 52.3% mean reduction at 12 weeks (RCT, n=86) 1.6mg subcutaneous twice weekly for 12–16 weeks Subcutaneous injection only Thymalin equivalent formulations KPV (…
Thymosin Alpha-1 NF- B inhibition, Treg upregulation Systemic immune modulation Phase 3 RCTs in sepsis 47% reduction in IL-6, 18% mortality reduction Gold-standard immunomodulator for systemic inflammation KPV NF- B translocation…